<DOC>
	<DOCNO>NCT01387399</DOCNO>
	<brief_summary>The purpose phase I study determine safety , feasibility , maximum tolerate dose ( MTD ) , pharmacokinetics pharmacodynamics Cisplatin administer Intraoperative Hyperthermic Intraperitoneal Chemoperfusion ( HIPEC ) Patients Platinum-Sensitive Recurrent Ovarian Cancer .</brief_summary>
	<brief_title>Safety Pharmacokinetics Intraoperative Hyperthermic Intraperitoneal Chemoperfusion ( HIPEC ) With Cisplatin Treat Platinum-sensitive Recurrent Ovarian Cancer</brief_title>
	<detailed_description>This phase I dose escalate study design identify tolerable , clinically active dos cisplatin deliver intraoperative intraperitoneal hyperthermic chemoperfusion ( HIPEC ) patient platinum-sensitive recurrent ovarian cancer . After surgical cytoreduction , single dose cisplatin administer 3 liter normal saline via intraperitoneal HIPEC closed-abdomen technique 90 minute hyperthermic phase ( 41-43 degree C ) . After completion perfusion , perfusate drain , abdomen open abdomen pelvis irrigate 2-3 liter normal saline wash away residual chemotherapeutic agent . Fascia skin close standard fashion . Cisplatin infusion discontinue unacceptable toxicity . The primary objective determine maximum tolerate dose ( MTD ) cisplatin administer HIPEC . Secondary objective determine pharmacokinetics pharmacodynamics well effect cisplatin HIPEC ability subsequently administer 6 cycle standard platinum-based systemic chemotherapy .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>female participant study sign informed consent patient histologically proven suspicious recurrent epithelial ovarian cancer ( base Response Evaluation Criteria Solid Tumors ( RECIST ) CA125 criterion ) Progressionfree interval completion adjuvant platinumbased chemotherapy 6 month . Subjects follow histologic epithelial cell type eligible : serous adenocarcinoma , endometrioid adenocarcinoma , undifferentiated carcinoma , clear cell adenocarcinoma , adenocarcinoma N.O.S . Patients eligible disease deem operable equal less 1 cm completion surgery . mucinous Ovarian cancer noninvasive Borderline tumor subject receive prior radiotherapy portion abdominal cavity pelvis exclude . Prior radiation localize cancer breast , head neck , skin permit , provide complete 3 year prior enrollment , subject remain free recurrent metastatic disease subject active infection require parenteral antibiotic patient underlie cardiac , pulmonary , metabolic , renal , hepatic gastrointestinal condition , chronic latent infectious disease , immune deficiency , history , opinion investigator , place patient unacceptable risk participation study patient know platinum allergy evidence extensive intraperitoneal adhesion time surgery , determine operating surgeon</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>recurrence</keyword>
	<keyword>platinum-sensitive recurrent ovarian cancer</keyword>
	<keyword>HIPEC</keyword>
	<keyword>intraperitoneal chemotherapy</keyword>
	<keyword>hyperthermic intraperitoneal chemoperfusion</keyword>
	<keyword>cisplatin</keyword>
</DOC>